Neurogene, Inc./$NGNE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Neurogene, Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Ticker

$NGNE
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
New York, United States

Employees

107

ISIN

US64135M1053
Website
www.neurogene.com

Neurogene, Inc. Metrics

BasicAdvanced
$303M
-
-$4.35
-
-

Bulls say / Bears say

Neurogene's NGN-401 gene therapy for Rett syndrome has received written agreement from the FDA for a registrational trial design, indicating regulatory support for its development. (ir.neurogene.com)
The company reported a strong cash position of $292.6 million as of March 31, 2025, providing a financial runway into the second half of 2027, which supports ongoing research and development activities. (ir.neurogene.com)
Neurogene's proprietary EXACT™ gene regulation technology has demonstrated potential to overcome limitations of conventional gene therapy in preclinical models, enhancing the company's competitive edge in the gene therapy market. (ir.neurogene.com)
Neurogene reported a net loss of $22.6 million for the first quarter of 2025, reflecting ongoing financial challenges common in clinical-stage biotech companies. (ir.neurogene.com)
The company's stock has experienced significant volatility, with a 45.13% decline over the past year, which may indicate investor concerns about the company's financial health and future prospects. (stocktitan.net)
Neurogene's reliance on a limited pipeline focused on rare neurological diseases means that any setbacks in clinical trials could have a disproportionate impact on the company's valuation and investor confidence. (neurogene.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Neurogene, Inc. News

AllArticlesVideos
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·1 week ago
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

Business Wire·1 week ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NGNE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs